Session VIII: Esophageal and Gastric Cancers

Chair(s)

• 

  Eric Van Cutsem, MD, PhD

  University Hospital Gasthuisberg/Leuven
  Leuven, Belgium
• 

  Andrés Cervantes, MD, PhD

  Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de Valencia
  Valencia, Spain

Presentations:

• 10:00 – 10:08

  SO-9: Pathological tumour and lymph node regression following neoadjuvant chemotherapy in resectable oesophagogastric cancer: Pooled analysis of 1619 patients from two randomised trial
  

  Abstract Presenter: Avani Athauda
• 10:08 – 10:16

  SO-10: The prognostic role of microarchitecture in tumour-positive lymph nodes in oesophageal cancer patients – results from the UK MRC OE02 trial
  

  Abstract Presenter: Maximilian Kloft
• 10:16 – 10:24

  SO-11: Response evaluation after neoadjuvant chemotherapy for resectable gastric cancer; downsizing vs downstaging
  

  Abstract Presenter: Alina Desiree Sandø
• 10:24 – 10:34

  Discussant: SO-9, SO-10, SO-11
  

  Discussant: Magali Svrcek, MD, PhD – Sorbonne Université, AP-HP, Hôpital Saint-Antoine
• 10:34 – 10:44

  Debate: GE Junction Tumors: Neoadjuvant Chemoradiotherapy (CRT) or Perioperative Chemotherapy (CT) - PRO CRT
  

  Debate Speaker: David H. Ilson, MD, PhD – Weill Cornell Medical College, Memorial Hospital, Memorial Sloan Kettering Cancer Center
• 10:44 – 10:54

  Debate: GE Junction Tumors: Neoadjuvant Chemoradiotherapy (CRT) or Perioperative Chemotherapy (CT) - PRO CT
  

  Debate Speaker: Salah-Eddin Al-Batran, Prof. Dr. – Krankenhaus Nordwest, Frankfurt
• 10:54 – 11:04

  Debate: GE Junction Tumors: Neoadjuvant Chemoradiotherapy (CRT) or Perioperative Chemotherapy (CT) - DISCUSSION
  

  Moderator: Eric Van Cutsem, MD, PhD – University Hospital Gasthuisberg/Leuven

  Moderator: Andrés Cervantes, MD, PhD – Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de Valencia

  Panelist: Karin Haustermans, MD, PhD – University Hospital Gasthuisberg

  Panelist: David H. Ilson, MD, PhD – Weill Cornell Medical College, Memorial Hospital, Memorial Sloan Kettering Cancer Center

  Panelist: Salah-Eddin Al-Batran, Prof. Dr. – Krankenhaus Nordwest, Frankfurt

  Panelist: Jerôme Durand-Labrunie, MD, MSc – Gustave Roussy
• 11:04 – 11:16

  LBA-1: RATIONALE-306: Randomized, global, Phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for locally advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC)
  

  Abstract Presenter: Harry Yoon
• 11:16 – 11:31

  Challenges with PDL Testing in Upper GI Cancer
  

  Speaker: Magali Svrcek, MD, PhD – Sorbonne Université, AP-HP, Hôpital Saint-Antoine
• 11:31 – 11:51

  Checkpoint Inhibition in Esophageal Cancer
  

  Speaker: Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center
• 11:51 – 12:11

  Checkpoint Inhibition in Gastric Cancer
  

  Speaker: Kei Muro, MD and PhD – Aichi Cancer Center Hospital
• 12:11 – 12:31

  New Targets and Agents in Upper GI Cancer
  

  Speaker: Florian Lordick, MD, PhD – Leipzig University Medical Center
• 12:31 – 12:50

  Endoscopic Management of Early Esophageal and Gastric Cancer
  

  Speaker: Raf Bisschops, MD, PhD – University Hospitals Leuven, KU Leuven